Roche’s Alzheimer’s Drug Shows Promise in Clinical Trial

by Kathy Jones on  October 11, 2011 at 7:26 PM Clinical Trials News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new drug being developed by Roche to treat Alzheimer's has found some success in a small clinical trial after a new report published in the Archive of Neurology revealed that it was able to remove amyloid plaques from the brains of Alzheimer's disease patients.
 Roche’s Alzheimer’s Drug Shows Promise in Clinical Trial
Roche’s Alzheimer’s Drug Shows Promise in Clinical Trial

The study was led by Dr Susanne Ostrowitzki in Switzerland and included 16 patients suffering from Alzheimer's. The researchers divided the patients into two groups, and each group was given two to seven infusions of intravenous gantenerumab of 60 mg or 200 mg strengths or placebo every four weeks.

The researchers found that gantenerumab was successfully able to remove amyloid plaques and slow down the progression of the disease when the patients were still functional. "Our study demonstrates that two to seven months of treatment with gantenerumab led to dose-dependent amyloid reduction in the brains of patients with Alzheimer's disease", Dr Ostrowitzki said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Signature Drug Toxicity Placebo Effects: Rare Insights 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive